<?xml version="1.0" encoding="UTF-8"?>
<p>Although remarkable progress in ZIKV research has created opportunities for the development of vaccines and therapeutics, some of which are currently advancing through clinical trials, the following key outstanding questions still remain to be addressed and should be the focus of future perspectives: 1) what is the mechanism by which ZIKV crosses the placenta and infects developing fetus? 2) What host and viral factors contribute to ZIKV persistence in the placenta and other immune-privileged sites? 3) What are the roles of noncoding RNAs during ZIKV infection? </p>
